Erwinase Master Treatment Protocol

Trial ID or NCT#

NCT00590915

Status

not recruiting iconNOT RECRUITING

Purpose

The purpose of this study is to make Erwinase available to patients with acute lymphoblastic leukemia (ALL) who have had previous allergic reactions to certain formulations of L-asparaginase.

Official Title

Erwinase Master Treatment Protocol

Eligibility Criteria

Sexes Eligible for Study: ALL
Accepts Healthy Volunteers: No
Inclusion Criteria:
  1. * Patient must give written informed consent to receive Erwinase.* Patient must be treated for acute lymphoblastic leukemia.* Patient must have either systemic hypersensitivity reactions to native (Elspar) or pegylated E.coli asparaginase (Oncaspar). This includes patients with generalized rash with or without anaphylactic symptoms, or patients with previously documented local or systemic reactions to E.coli derived L-asparaginase.
Exclusion Criteria:
  1. * Previous allergic reaction to Erwinia L-asparaginase (Erwinase)* Previous acute pancreatitis* Pregnant or lactating woman
View All Criteria
Show Less

Investigator(s)

Neyssa Marina

Contact us to find out if this trial is right for you.

Contact

Peds Hem/Onc CRAs
650-723-5535

View on ClinicalTrials.gov